within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA48_Belumosudil;

model Belumosudil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.46,
    Cl = 2.7305555555555558e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.151,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0105,
    Tlag = 15.0);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Belumosudil</td></tr><tr><td>ATC code:</td><td>L04AA48</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>151</td><td>L</td></tr>
    <tr><td>clearance:</td><td>9.83</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Belumosudil is an orally administered, selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). It is approved for the treatment of chronic graft-versus-host disease (cGVHD) in adults and pediatric patients aged 12 years and older who have received at least two prior lines of systemic therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult healthy volunteers and patients with cGVHD, based primarily on product labeling and limited clinical trial reports.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AA48 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Belumosudil;
